Guiso et al. Recommend that "ELISA and multiplex immunoassays should use purified non-detoxified PT as an antigen...The group discourages using other antigens as they are not specific". Riffelmann et al. Compare the performance of a variety of pertussis antibody kits, including the Serion PT+FHA assay used in this study. They showed a linear response with anti-PT IgG concentrations when PT-alone was used as the coating antigen. "Kits containing a mixture of antigens showed a skewed relation to to the reference preparations ... and no linear regression could be constructed. They also found that the use of PT alone was required to assign units which correspond to the FDA units that the Serion assay claims to report. It is concerning that the Serion PT+FHA ELISA had a specificity of only 56%, suggesting that the values in sera with low values will be unreliable. Thus the study uses a poor assay and one that will not allow comparison with past or future studies. Before this paper is published, the limitations of the pertussis IgG ELISA must be made clear in the discussion.
Specific comments
Methods. Pertussis ELISA. It is inappropriate to define the response as FDA units as by definition, these are defined against single antigens and not for a mixed coating antigen. The kit manufacturer is incorrect to call thee FDA units (see Riffelmann et al. 2010) .
Results I would suggest that figures 1 and 2 are not required as the data is presented in Table 3 Discussion P14 line 42 The authors state that the main limitation of the study is the modest number of subjects. They should also include a discussion of the pertussis IgG assay used and how a PT only ELISA should be used in future studies. P15 line 3. There is much evidence that direct comparison between PT IgG values obtained using different assays is possible when international reference standards are used. P15 lines 11-27. The authors describe that IgG to polysaccharide antigens is transferred across the placenta less efficiently as it is IgG2. They should make clear that the vaccines used currently are conjugates that have a greater IgG1/IgG2 response than plain polysaccharides. P15 lines 30-49. The authors should mention that with the low levels of IgG detected, the assays used will be close to their lower limit of detection as thus the values obtained may be affected by assay performance. It would be helpful to know the LLOD of the assays to aid interpretation. P17 Line 53. "...no validated correlate of protection for pneumococcus.." Various efficacy studies of pneumococcal conjugate vaccines have provided serotype-specific IgG levels that correlate with protection. These cannot be related to the current study due to the mixed coating antigen used here. P18 lines 12-18. Make it clear that these studies were with plain polysaccharide (unconjugated) vaccines. Introduction -page 7 line13: is it possible to update for the whole year 2012? -page 7 line 30: is it possible to provide a source on internet/publication in the meanwhile? Methods -Page 9 line 3: how much blood was taken? Where was it taken from the infant and why not use cord blood? -Page 9 line 30: Pertussis titers >50FDA. Please explain FDA and do you mean for both PT and FHA together? What is a pertussis IgG response: PT or FHA or both together? Results -Page 11 line32: you measured anti-PT and anti-FHA (methods section). Which one do you mean when you describe "specific antibody to pertussis Tables 2 and 3 . You use the specific antibody titers and not GMC to calculate the median placental transfer. However, you describe no differences in 
VERSION 1 -AUTHOR RESPONSE
Reviewer 1: Prof Andrew Gorringe 1.1 We thank the reviewer for his thorough assessment of our laboratory methods, which led to some technical questions which we address in detail below. It is important to state however, as the reviewer acknowledges himself: "the message that IgG levels are low in most subjects is not called into question". In his general comments Professor Gorringe criticizes our use of a commercial pertussis ELISA using mixed PT/FHA coating antigens (Serion Elisa Classic Bordetella Pertussis IgG) and questions the validity of the pertussis results. The manufacturers report the performance characteristics of the assay as >99% sensitivity and > 99% specificity, and Kosters et al 2000 report sensitivity and specificity of 95%. However, as noted by Prof Gorringe, Riffelman et al 2010, compared this assay to an in-house ELISA reference standard and report a high sensitivity (86%) but low specificity (56%). We accept that if the specificity of this assay is lower than that stated by the manufacturer we may have overestimated the proportion of mothers in our study demonstrating a higher level of antibody to pertussis. Our main finding that pertussis antibody levels in this cohort are worryingly low remains unchanged. If anything we may have underestimated the proportion of mothers and infants susceptible to pertussis, the major clinical issue in this study. Prof Gorringe also refers to a second paper, Guiso et al who "Recommend that "ELISA and multiplex immunoassays should use purified non-detoxified PT as an antigen... Guiso et al recommend that only PT-specific antibodies are measured for the diagnosis of pertussis, due to concerns regarding low specificity of other antigens such as FHA. However, Guiso et al also state that "the measurement of other antibodies may be used for transmission, immunogenicity and vaccine studies" In immunogenicity studies, particularly in a disease where immune correlates of protection are not well understood, an assay that is more sensitive than specific, and includes more than one vaccine antigen, may be appropriate. As noted by Guiso et al, both PT and FHA are present in significant amounts in all licensed vaccines in Europe. Since our cohort study included a follow-up phase (data not reported here) which examined infant vaccine response, we believe that use of an assay which measures both PT and FHA was appropriate for the purposes of this study. In summary, we acknowledge the concerns regarding the assay used, and state this in our discussion, but do not believe this alters the public health utility of the data or the overall conclusions of the study. A paragraph has been added to our discussion as follows: "Another potential limitation of this study is the use of a mixed pertussis antigen (PT/FHA) ELISA to assess antibody response. This assay was chosen to allow comparison to previously published work18 and because both PT and FHA are vaccine antigens present in all licensed vaccines in Europe. The use of ELISAs that measure these antibodies separately may however have allowed easier comparison to other studies. Another concern is that mixed antigen assays have been found to be less specific in the diagnosis of pertussis.44 Published recommendations for the diagnosis of pertussis infection state that PT-specific antibodies alone should be measured, however this recommendations acknowledged that measurement of antibodies to other pertussis antigens may be appropriate in immunogenicity studies.45 Although both sensitivity and specificity of the assay used in this study have previously been reported to be 95%46, a more recent study reported specificity to be only 56%.44 If the specificity of our pertussis assay is low we may have overestimated maternal specific pertussis antibody levels, and therefore may have underestimated the proportion of mothers and infants susceptible to pertussis. Our main conclusion, that pertussis antibody levels in this cohort are worryingly low, remains unchanged."
1.2 "The authors should modify their description of the pertussis ELISA as it does not, as claimed by manufacturer, report FDA units."
The reporting of results as FDA units was an error on our part. The manufacturer"s package insert states that the reference standard is WHO International Standard 06/140 and results should be reported in IU/ml. We have amended our results and figures to report in IU/ml rather than FDA U/ml.
1.3 "The performance of the assay with lower limit of detection needs to be described to allow interpretation of the results."
We have changed the methods section to indicate the limit of quantification for all assays, and clarified our data-handling of results outside of these limits as follows: "Where assay results were below the lower limit of quantification an arbitrary value of half the lower limit was assigned: anti-Pertussis IgG 5IU/ml,; anti-Tetanus IgG 0.025 IU/ml; anti-Hib IgG 0.05mg/dl; anti-PCP IgG 1.65 mg/dl. Where assay results were above the upper limit of quantification samples were re-tested with serial dilutions until a measurable value was obtained. This value was then multiplied according to the dilution factor to obtain the antibody level." Specific comments 1.4 Methods. "Pertussis ELISA. It is inappropriate to define the response as FDA units as by definition, these are defined against single antigens and not for a mixed coating antigen. The kit manufacturer is incorrect to call these FDA units (see Riffelmann et al. 2010) . " See response to 1.2 1.5 Results "I would suggest that figures 1 and 2 are not required as the data is presented in Table 3 and the overall GMCs are provided in the text."
We feel that these figures allow readers to better understand the distribution of results, which is particularly relevant since results are highly variable between individuals. This variability is not fully reflected in the GMC stated in the text. We have also altered figures 1 and 2 to show HIV and non HIV exposed mothers and infants separately in line with comments from Reviewer 2. We feel this justifies the inclusion of these figures. We have changed Table 3 to a supplementary table (2) , although we would be happy for this table to be included in the main manuscript if the editors feel this is appropriate. Yes, the assay used was The Binding Site anti-PCP IgG assay, as stated in the methods section. Binding Site has offices throughout Europe. We have added the following on page 10, line 12 to clarify this: "using the same assay" 1.7 " P14 line 42 The authors state that the main limitation of the study is the modest number of subjects. They should also include a discussion of the pertussis IgG assay used and how a PT only ELISA should be used in future studies." See response to 1.1 1.8 "P15 line 3. There is much evidence that direct comparison between PT IgG values obtained using different assays is possible when international reference standards are used."
The majority of studies on maternal antibody and placental transfer we reference report antibodies to multiple antigens, not just PT. All of the pertussis studies we reference pre-date the current international standard, introduced in 2009. However, for brevity we have removed the sentence "Although direct comparison is problematic due to international differences in laboratory measures and reference standards used.." 1.9 "P15 lines 11-27. The authors describe that IgG to polysaccharide antigens is transferred across the placenta less efficiently as it is IgG2. They should make clear that the vaccines used currently are conjugates that have a greater IgG1/IgG2 response than plain polysaccharides."
Since the mothers in our cohort would not have received these conjugate vaccines we think this is irrelevant, however for clarity we have added the following paragraph to the discussion: "Conjugate vaccines are now available to Hib and Pneumococcus, which could potentially elicit a greater IgG1 response. Since these vaccines were only introduced in the UK in 1992 and 2006 respectively, we would expect very few of the mothers in our cohort (median age 31.84) to have received these vaccines. Therefore any maternal antibody response is likely to reflect natural exposure to polysaccharide, resulting in a predominant IgG2 response and consequent reduced placental transfer." 1.10 "P15 lines 30-49. The authors should mention that with the low levels of IgG detected, the assays used will be close to their lower limit of detection as thus the values obtained may be affected by assay performance. It would be helpful to know the LLOD of the assays to aid interpretation" See response to 1.3 1.11 "P17 Line 53. "...no validated correlate of protection for pneumococcus.." Various efficacy studies of pneumococcal conjugate vaccines have provided serotype-specific IgG levels that correlate with protection. These cannot be related to the current study due to the mixed coating antigen used here." This sentence has been altered to "While there is no validated correlate of protection for collective response to multiple pneumococcal serotypes…" 1.12 "P18 lines 12-18. Make it clear that these studies were with plain polysaccharide (unconjugated) vaccines."
This paragraph already includes the sentence "Included trials were limited by small sample size, and all used the pneumococcal polysaccharide vaccine." However, for clarity we have amended this sentence to ""Included trials were limited by small sample size, and all used the (unconjugated) pneumococcal polysaccharide vaccine." Reviewer 2: Dr Elke Leuridan 2.1."There are results of a small group of HIV positive women included in the results of the larger group. This is, regarding the small sample size, this distorts the results. At least, the subjects with HIV or children of HIV bearing mothers, should be indicated in the figures. "
Since there was no difference in GMC between the HIV infected and uninfected mothers reporting the group as a whole does not distort the results. For infants, the only difference in GMC between HIV exposed and unexposed infants was in antibody titres to pneumococcus -however inclusion of these infants in analysis of the cohort as a whole did not significantly change the overall GMC. We now present this data in a supplementary table and have added the following statement to the Results section: "There was no significant difference in specific antibody titres between HIV-infected and HIV uninfected women in this cohort (Figure 1) and inclusion of the data from HIV-infected women in the overall analysis did not significantly alter the results (supplementary table 1)" 2.2 ."For pertussis: in the methodology the ELISA method is described for detecting both Pertussis toxin and FHA, but in the results, authors only mention: pertussis antibody: which one do they mean? and if they count both together, what is the meaning of that value?"
The assay measures a collective response to PT/FHA, this is the value reported. We now clarify this in our methods as follows: "This assay measures antibody response to the antigens PT and FHA. Results are reported as a collective IgG response to these pertussis antigens." As discussed in the methods, since there is no established correlate of protection for either single or multiple pertussis antigens, the results should be interpreted according to the manufacturer"s instructions where a total Pertussis IgG response >50 IU/ml is regarded as positive. It is established in the literature that a "positive" or detectable diagnostic test may be consistent with some measure of protection. As discussed in 1.1 we accept that an assay which measured PT and FHA separately may have allowed easier comparison with other studies and include this in our discussion.
2.3 "Page 13 line 3-25. Tables 2 and 3 . You use the specific antibody titers and not GMC to calculate the median placental transfer. However, you describe no differences in table 3 (except for pneumococcus p value .019) between GMC in either hiv positive or non hiv positive women and their respective offspring. Why did you not use GMC in the calculations of the placental transfer? I doubt if you would find the same reduction in transfer capacities."
It is standard practice to calculate placental transfer ratio by the ratio of individual infant: maternal specific antibody. In our study median placental transfer ratio is reported rather than the arithmetic or geometric mean because the data is not normally (or log-normally) distributed. A "total" ratio of population means (ie a ratio of infant GMC: Maternal GMC), while reported in some studies, is less clinically meaningful, since placental transfer is dependent on numerous factors which vary between individuals, and it is not possible to statistically compare groups using this ratio (since t-tests and their non-parametric equivalent compare population distributions). However, to address Dr Leuridan"s concerns we have calculated the total GMC ratio for placental transfer and found a very similar reduction in transfer capacities. We state this in the results as follows and present the data in a supplementary table: "When the total placental transfer ratio (based on the ratio of the total infant population GMC to the total maternal population GMC was analysed, a similar reduction in placental transfer was observed in the context of maternal HIV infection. (Supplementary Table 3 )" General 2.4 "Since placental transport is limited in HIV positive women despite appropriate treatment, would you suggest to recommend the Tdap vaccination during pregnancy with more attention to high risk groups? Placental dysfunction is also known to occur in other pregnancy associated diseases eg hypertensive pregnant women."
Our data are indicative but not definitive in this regard and we would wish to base public health recommendations on larger studies of specific risk groups.
2.5 "Page 6 line 49: There is no correlate of protection known for pertussis IgG antibodies, therefore it is hard to suggest "protection". Better use presence/ high amount of antibodies instead of protection."
The word protective has been removed and this line has been changed to "This study provides recent data on baseline levels of specific antibody in mothers and newborns to vaccine preventable infections in a UK cohort." 2.6 "-page 7 line13: is it possible to update for the whole year 2012?"
The information has been updated in the introduction as follows: "In 2012 there were 9741 laboratory confirmed cases of pertussis in England and Wales, almost ten times more than in 2011 (1119 cases) or in 2008 (902 cases), the last peak year1. The highest incidence of disease has been observed amongst infants less than 3 months of age, with all 14 pertussis-related deaths in 2012 observed in this age group." 2.7 -"page 7 line 30: is it possible to provide a source on internet/publication in the meanwhile?"
The appropriate website URL has been added to the references.
2.8" -Page 9 line 3: how much blood was taken? Where was it taken from the infant and why not use cord blood?" 1ml of blood was taken from the infants and 2ml from the mothers. Infant samples used capillary and maternal samples venous blood as stated in the methods. Cord blood was not used for logistical reasons, as most mothers were recruited on the postnatal ward following delivery, within the indicated timeframes. The methods section has been amended to clarify this: "2ml of maternal peripheral venous blood and 1ml of infant capillary blood was collected. All samples were taken within 72 hours of delivery"
